Kiniksa Pharmaceuticals International (KNSA) Common Equity (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Common Equity for 10 years, with the latest figure at $605.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 32.39% year-over-year to $605.7 million; the trailing twelve-month figure through Mar 2026 stood at $605.7 million (up 32.39% YoY), and the FY2025 full-year result was $567.6 million, up 29.46% from the prior year.
• Common Equity for Q1 2026 stood at $605.7 million, up from $567.6 million in the prior quarter.
• The five-year high for Common Equity was $605.7 million in Q1 2026, with the low at $153.5 million in Q2 2022.
• Historically, Common Equity has averaged $420.5 million across 5 years, with a median of $435.1 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity tumbled 38.59% — and 2023, when it surged 168.19%.
• Kiniksa Pharmaceuticals International's Common Equity stood at $396.1 million in 2022, then grew by 10.78% to $438.8 million in 2023, then retreated by 0.09% to $438.4 million in 2024, then gained by 29.46% to $567.6 million in 2025, then advanced by 6.71% to $605.7 million in 2026.
• The last three Common Equity figures came in at $605.7 million (Q1 2026), $567.6 million (Q4 2025), and $535.4 million (Q3 2025), per Business Quant data.